Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy

ConclusionMetaBC is poorly responsive to NAC, with a pCR rate (11%), that is lower than expected in a predominantly TNBC cohort. MetaBC patients should be considered for clinical trials testing new NAC regimens and in the absence of clinical trial enrollment, MetaBC patients with resectable disease should proceed directly to definitive operative management.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research